Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life

Vaccine

Volumn 14, Issue 8, 1996, Pages 767-772

  Halperin, S A ^a   Eastwood, B J ^b   Barreto, L ^c   Friesen, B ^d   Medd, L ^e   Meekison, W ^f   Guasparini, R ^g  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Division of Pathology   (Canada)

^d South Calgary Health Centre   (Canada)

^e Boundary Health Unit   (Canada)

^f Simon Fraser Health Unit   (Canada)

^g Central Fraser Health Unit   (Canada)

Author keywords

Acellular pertussis vaccine; Adverse reactions; Immunogenicity

Indexed keywords

DIPHTHERIA TOXIN; PERTUSSIS VACCINE; TETANUS TOXOID;

ANTIBODY RESPONSE; ARTICLE; CANADA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIPHTHERIA; DRUG SAFETY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TETANUS; VOMITING;

EID: 0030175441     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00250-5     Document Type: Article

References (45)

1. 1 Centers for Disease Control. Summary of notifiable diseases, United States, 1991 Morbid. Mortal. Wkly Rep. 1991, 40, 57-63
2. 2 Varughese, P. Incidence of pertussis in Canada. Can. Med. Assoc. J. 1985, 132, 1041-1042
3. 3 Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines Howson, C.P. Howe, C.J. Fineberg, H.V. Adverse Effects of Pertussis and Rubella Vaccines 1991, 171-177. National Academy Press, Washington, DC
4. 4 Cody, C.L., Baraff, L.J., Cherry, J.D. et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981, 68, 650-660
5. 5 Centers for Disease Control. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use -supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly Rep. 1992, 41(RR-1), 1-10
6. 6 Centers for Disease Control. Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series; update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly Rep. 1992, 41(RR-15), 1-5
7. 7 Committee on Infectious Diseases. Acellular pertussis vaccines: recommendations for use as the fourth and fifth doses. Pediatrics 1992, 90, 121-123
8. 8 Edwards, K.M. Acellular pertussis vaccines - a solution to the pertussis problem? J. Infect. Dis. 1993, 168, 15-20
9. 9 Aoyama, T., Murase, Y., Kato, M., Iwai, H. and Iwata, T. Efficacy and immunogenicity of acellular pertussis vaccine by manufacturer and patient age. Am. J. Dis. Child. 1989, 143, 655-659
10. 10 Mortimer, E.A. Jr., Kimura, M., Cherry, J.D. et al. Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am. J. Dis. Child. 1990, 144, 899-904
11. 11 Schmidt, H.-J. Results of a household contact protective study. Abstract. Presented at Caring for the New Generation, Sorrento, Italy, 6-7 April 1995, p. 37
12. 12 Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events, Lancet 1988, 1, 955-960
13. 13 Marwick, C. Acellular pertussis vaccine hailed for infants. J. Am. Med. Assoc. 1995, 274, 446-447
14. 14 Trollfors, B., Taranger, J., Lagergård, T. et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 1995, 333, 1045-1050
15. 15 National Advisory Committee on Immunization Pertussis Vaccine. Canadian Immunization Guide Fourth 1994, 85-89. Health and Welfare Canada, Ottawa
16. 16 Centers for Disease Control. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Immunization Practices Advisory Committee (ACIP). Morbid. Mental. Wkly Rep. 1991, 40(No. RR-10), 1-28
17. 17 Halperin, S.A., Barreto, L., Eastwood, B.J., Law, B. and Roberts, E.A. Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. Archs Pediatr. Adolesc. Med. 1994, 148, 1220-1224
18. 18 Halperin, S.A., Barreto, L., Friesen, B. and Meekison, W. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. Archs Pediatr. Adolesc. Med. 1994, 148, 495-502
19. 19 Glode, M., Joffe, L., The Children's Medical Center et al. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17-to 24-month-old children. Pediatr. Infect. Dis. J. 1992, 11, 530-535
20. 20 Feldman, S., Perry, C.S., Andrew, M. et al. Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15-to 24-month-old children. J. Pediatr. 1992, 121, 857-861
21. 21 Bernstein, H.H., Rothstein, E.P., Pennridge Pediatric Associates et al. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15-through 20-month-old infants. Pediatrics 1994, 93, 659
22. 22 Pichichero, M.E., Badgett, J.T., Rodgers, G.C., McLinn, S., Trevino-Scatterday, B. and Nelson, J.D. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18-to 24-month old children. Pediatr. Infect. Dis. J. 1987, 6, 352-363
23. 23 Blumberg, D.A., Mink, C.M., Cherry, J.D. et al. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17-to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. J. Pediatr. 1990, 117, 46-51
24. 24 Marcinak, J.F., Ward, M., Frank, A.L., Boyer, K.M., Froeschle, J.E. and Hosbach, P.H. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15-to 20-month-old children. Am. J. Dis. Child. 1993, 147, 290-294
25. 25 Bernstein, D.I., Smith, V.E., Schiff, G.M., Rathfon, H.M. and Boscia, J.A. Comparison of acellular pertussis vaccine with whole cell vaccine as a booster in children 15 to 18 months and 4 to 6 years of age. Pediatr. Infect. Dis. J. 1993, 12, 131-135
26. 26 Edwards, K.M., Bradley, R.B., Decker, M.D. et al. Evaluation of a new highly purified pertussis vaccine in infants and children. J. Infect. Dis. 1989, 160, 832-837
27. 27 Siber, G.R., Thakrar, N., Yancey, B.A. et al. Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. Vaccine 1991, 9, 735-740
28. 28 Englund, J.A., Decker, M.D., Edwards, K.M., Pichichero, M.E., Steinhoff, M.C. and Anderson, E.L. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics 1994, 93, 37-43
29. 29 Blennow, M. and Granström, M. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants Pediatrics 1989, 84, 62-67
30. 30 Edwards, K.M., Decker, M.D., Bradley, R.B., Taylor, J.C. and Hager, C.C. Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines Pediatr. Infect. Dis. J. 1991, 10, 315-318
31. 31 Pichichero, M.E., Francis, A.B., Marsocci, S.M., Green, J.L., Disney, F.A. and Meschievitz, C. Safety and immunogenicity of an acellular pertussis vaccine booster in 15-to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants. Pediatrics 1993, 91, 756-760
32. 32 Blumberg, D.A., Mink, C.M., Cherry, J.D. et al. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. J. Pediatr. 1991, 119, 194-204
33. 33 Manclark, C.R., Meade, B.D., Burstyn, D.G. Rose, N.R. Friedman, H. and Fahey, J.L. Manual of Clinical Laboratory Immunology 3rd 1986, 388-394. American Society for Microbiology, Washington, DC
34. 34 Gillenius, P., Jäätmaa, E., Askelöf, P., Granström, M. and Tiru, M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J. Biol. Stand. 1984, 13, 61-66
35. 35 Breslow, N.E. and Day, N.E. Statistical Methods in Cancer Research, Vol. II The Design and Analysis of Cohort Studies 1987, 108-113. International Agency for Research on Cancer, Lyon, France
36. 36 Podda, A., De Luca, E.C., Contu, B. et al. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. J. Pediatr. 1994, 124, 921-926
37. 37 Pichichero, M.E., Francis, A.B., Blatter, M.M. et al. Acellular pertussis vaccination of 2-month-old infants in the United States. Pediatrics 1992, 89, 882-887
38. 38 Anderson, E.L., Belshe, R.B. and Bartram, J. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. J. Infect. Dis. 1988, 157, 731-737
39. 39 Pichichero, M.E., Francis, A.B., Marsocci, S.M., Green, J.L. and Disney, F.A. Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole cell pertussis vaccine in infants. Am. J. Dis. Child. 1993, 147, 295-299
40. 40 Pichichero, M.E., Green, J.L., Francis, A.B., Marsocci, S.M., Lynd, A.M. and Litteer, T. Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in two-month-old children. Pediatr. Infect. Dis. J. 1994, 13, 183-186
41. 41 Baker, J.D., Halperin, S.A., Edwards, K., Miller, B., Decker, M. and Stephens, D. Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. J. Pediatr. 1992, 121, 523-527
42. 42 Halperin, S.A., Mills, E., Barreto, L., Pim, C. and Eastwood, B.J. Acellular pertussis vaccine as a booster dose for 17 to 19 month old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatr. Infect. Dis. J. 1995, 14, 792-797
43. 43 Edwards, K.M., Meade, B.D., Decker, M.D. et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995, 96, 548-557
44. 44 Decker, M.D., Edwards, K.M., Steinhoff, M.C. et al. Comparison of 13 acellular pertussis vaccines: adverse reactions Pediatrics 1995, 96, 557-566
45. 45 Englund, J.A., Glezen, W.P. and Barreto, L. Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J. Infect. Dis. 1992, 166, 1436-1441